PT94761A - Processo para a preparacao de muteinas da eritropoetina humana e de composicoes farmaceuticas que as contem - Google Patents

Processo para a preparacao de muteinas da eritropoetina humana e de composicoes farmaceuticas que as contem

Info

Publication number
PT94761A
PT94761A PT94761A PT9476190A PT94761A PT 94761 A PT94761 A PT 94761A PT 94761 A PT94761 A PT 94761A PT 9476190 A PT9476190 A PT 9476190A PT 94761 A PT94761 A PT 94761A
Authority
PT
Portugal
Prior art keywords
human
muteins
eritropoetine
preparation
pharmaceutical compositions
Prior art date
Application number
PT94761A
Other languages
English (en)
Other versions
PT94761B (pt
Inventor
Mathias Fibi
Gerd Zettlmeissl
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of PT94761A publication Critical patent/PT94761A/pt
Publication of PT94761B publication Critical patent/PT94761B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT94761A 1989-07-20 1990-07-19 Processo para a preparacao de muteinas da eritropoetina humana e de composicoes farmaceuticas que as contem PT94761B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3923963A DE3923963A1 (de) 1989-07-20 1989-07-20 Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Publications (2)

Publication Number Publication Date
PT94761A true PT94761A (pt) 1991-03-20
PT94761B PT94761B (pt) 1997-03-31

Family

ID=6385421

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94761A PT94761B (pt) 1989-07-20 1990-07-19 Processo para a preparacao de muteinas da eritropoetina humana e de composicoes farmaceuticas que as contem

Country Status (13)

Country Link
US (1) US5457089A (pt)
EP (1) EP0409113B1 (pt)
JP (1) JP3062583B2 (pt)
KR (1) KR0183981B1 (pt)
AT (1) ATE139261T1 (pt)
AU (1) AU638470B2 (pt)
CA (1) CA2021528C (pt)
DE (2) DE3923963A1 (pt)
DK (1) DK0409113T3 (pt)
ES (1) ES2090061T3 (pt)
GR (1) GR3020517T3 (pt)
IE (1) IE902643A1 (pt)
PT (1) PT94761B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263845B1 (ko) * 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
EP0667903A1 (en) * 1992-07-28 1995-08-23 New England Deaconess Hospital Recombinant human erythropoietin with altered biological activity
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
KR960701650A (ko) * 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US6506595B2 (en) * 1998-03-31 2003-01-14 Itoham Foods Inc. DNAs encoding new fusion proteins and processes for preparing useful polypeptides through expression of the DNAs
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
WO1999054486A1 (en) 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
CN100338091C (zh) * 1999-09-25 2007-09-19 伊藤火腿株式会社 编码新的融合蛋白的dna和通过该dna的表达来制备有用的多肽的方法
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
AU7338501A (en) * 2000-09-08 2002-03-22 Gryphon Sciences Polymer-modified synthetic proteins
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1326969B1 (en) 2000-09-25 2009-04-15 Genetronics, Inc. Improved system for regulation of transgene expression
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
PT1465987E (pt) * 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
DE602004027483D1 (de) * 2003-05-23 2010-07-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
KR100632985B1 (ko) * 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
CN1897959A (zh) * 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
WO2005037304A1 (en) * 2003-10-17 2005-04-28 Crucell Holland B.V. Treatment and prevention of decubitus
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
AU2005235794A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
AU2006316450A1 (en) * 2005-11-24 2007-05-31 Merck Serono Sa Erythropoietin polypeptides and uses thereof
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
KR100700039B1 (ko) * 2007-01-31 2007-03-26 이수왕 음료용 병
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
UA106731C2 (uk) 2008-09-26 2014-10-10 Амбркс, Інк. Модифіковані поліпептиди еритропоетину тварин та їх застосування
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition

Also Published As

Publication number Publication date
GR3020517T3 (en) 1996-10-31
CA2021528C (en) 2001-09-11
IE902643A1 (en) 1991-02-27
DK0409113T3 (da) 1996-10-07
AU5914590A (en) 1991-01-24
US5457089A (en) 1995-10-10
AU638470B2 (en) 1993-07-01
ES2090061T3 (es) 1996-10-16
PT94761B (pt) 1997-03-31
DE59010367D1 (de) 1996-07-18
DE3923963A1 (de) 1991-01-31
KR0183981B1 (ko) 1999-04-01
EP0409113A1 (de) 1991-01-23
JPH0372885A (ja) 1991-03-28
KR910003102A (ko) 1991-02-26
ATE139261T1 (de) 1996-06-15
CA2021528A1 (en) 1991-01-21
EP0409113B1 (de) 1996-06-12
JP3062583B2 (ja) 2000-07-10

Similar Documents

Publication Publication Date Title
PT94761A (pt) Processo para a preparacao de muteinas da eritropoetina humana e de composicoes farmaceuticas que as contem
PT87261A (pt) Processo de preparacao de heparinas de baixo peso molecular,com estrutura regular e de composicoes farmaceuticas que as contem
PT95082A (pt) Processo para a preparacao de amino acidos isentos de lactamas e de composicoes farmaceuticas que os contem
PT83013B (pt) Processo para a preparacao de hidroxialquilxantinas terciarias, e de composicoes farmaceuticas que as contem
PT98102A (pt) Processo de preparacao de misturas de polissacaridos de baixo peso molecular e de composicoes farmaceuticas que as contem
DE3882383T2 (de) Phospholipidische Komplexe aus Vitis Vinifera-Extrakten, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische und kosmetische Zusammensetzungen.
PT89094A (pt) Processo para a preparacao de 1-aril-3-quinolina-e 1-aril-3-isoquinolina-carboxamidas e de composicoes farmaceuticas que as contem
NO170126C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater i form av suspensjoner som inneholder sucralfat
PT81969B (pt) Processo para preparacao de 11 beta-fenil-esteroides e de composicoes farmaceuticas que os contem
PT87880A (pt) Processo para a preparacao de composicoes farmaceuticas anti-virais que contem ciclo-dextrinas
ES2024400A4 (es) Extracto de hojas de ginkgo biloba, su metodo de preparacion y productos que contienen el extracto.
ATE81014T1 (de) Procyanidol-oligomerische fraktionen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
PT84702B (pt) Processo para a preparacao de 1-hidroxi-2-piridonas, de composicoes farmaceuticas que as contem e dos produtos intermediarios para a sua preparacao
PT89655B (pt) Processo para a preparacao de novas lactamas substituidas e de composicoes farmaceuticas que as contem
PT84358B (pt) Processo para a preparacao de naftotiazepinonas e de composicoes farmaceuticas que as contem
PT91870A (pt) Processo para apreparacao de novas quinoliloxazol-2-onas e de composicoes farmaceuticas que as contem
DE69012650T2 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
PT97884A (pt) Processo para a preparacao de derivados de radicicol e de composicoes farmaceuticas que os contem
ES2060078T3 (es) Glicolipido vegetal positivo al ensayo de limulus y metodo de estimular el sistema inmunitario de un animal.
PT98816A (pt) Processo para a preparacao de tienodiazepinas e de composicoes farmaceuticas que as contem
PT94595A (pt) Processo para a preparacao de triodo-5-aminoisoftaldiamidas substituidas e de composicoes de contraste radiograficas que as contem
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
PT87298A (pt) Processo de preparacao de androstanos 2beta, 16beta-diamino-3alfa, 17alfa-oxigenados e de composicoes farmaceuticas que os contem
PT90787A (pt) Processo para a preparacao de 3-amino-sindnoniminas substituidas e de composicoes farmaceuticas que as contem
PT81606B (pt) Processo para a preparacao de novas substancias derivadas da pluramicina com actividade anti-tumor e de composicoes faramceuticas que as contem

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19901019

FG3A Patent granted, date of granting

Effective date: 19961216

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20111216